Tags : Diabetes

MedTech Regulatory

Abbott’s FreeStyle Libre 2 Receives Health Canada’s Approval for Adults

Shots: Abbott’s next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received Health Canada’s approval for adults & children with diabetes The system continuously measures glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high/low without scanning The technology sustains performance for ~14days, providing trends, insights & actionable data […]Read More

MedTech

Medtronic Launches InPen Integrated with CGM Data for People with

Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020 The integrated system provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes through a single smartphone app InPen is the […]Read More

MedTech

Eli Lilly Collaborates with Dexcom for Diabetes Management

Shots: The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, including giving visibility to the benefits of a new mealtime insulin HCPs treating T1D & T2D will be able to assess their patient’s glucose levels […]Read More

Clinical Trials Pharma

Eli Lilly Reports Results of Jardiance (empagliflozin) in P-III EMPEROR

Shots: The P-III EMPEROR Trial involves assessing of Jardiance (10 mg) vs PBO in two studies EMPEROR-Reduced [NCT03057977, N=3,730] & EMPEROR-Preserved [NCT03057951, N=5,990] in patients with HFrEF & HFpEF respectively The EMPEROR-Reduced study meets its 1EPs in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure while the overall […]Read More

DigiHealth

Sanofi and Abbott Collaborate to Assimilate Glucose Sensing and Insulin

Shots: Abbott and Sanofi team up to develop tools integrating their blood sugar tracking and insulin delivery technologies to help diabetes patients in managing their conditions The non-exclusive agreement will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens, apps and cloud software currently in development, allowing patients & doctors to […]Read More